Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
Less than 10 years ago surgery and watchful-waiting were the only widely accepted management options for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and benign prostatic obstruction (BPO). There has been an enormous decline in the popularity of surgery and it is now apparent that medication is the most frequently used treatment for BPH/LUTS; this has arguably therefore been the most major change in urological clinical practice in the last decade. Currently alpha(1)-adrenoceptor antagonists are the commonest medical therapy, and are thought to act by relaxing prostatic smooth muscle, the neural or so-called 'dynamic' component of BPO. 5alpha-reductase inhibitors (finasteride, dutasteride) are another option for BPH/LUTS, which reduce prostatic mass and therefore the mechanical or 'static' component of BPO. In the last 10 years there have been four direct comparative studies between alpha(1)-adrenoceptor antagonists and finasteride, including their combination, the results of which, and their implications for therapy, are discussed. Another group of agents are the phytotherapeutic extracts, which act via various mechanisms, many as yet poorly defined. This review critically assesses existing publications relating to the medical management of BPH/LUTS.
Chapple
Christopher R
CR
Department of Urology, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, UK. c.r.chapple@sheffield.ac.uk
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors*; D004338:Drug Combinations; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D008517:Phytotherapy / Q000379:methods; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D016055:Urinary Retention / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D004338:Drug Combinations; D018727:Muscarinic Antagonists; D042944:Cholestenone 5 alpha-Reductase